Meyka Pro banner
Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation Fundamental Analysis (NASDAQ: ADPT)

ADPT●NASDAQ
HealthcareBiotechnology
$30.26
$2.28(8.15%)
U.S. Market opens in 15h 50m

Adaptive Biotechnologies Corporation Fundamental Analysis (NASDAQ: ADPT)

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) shows moderate financial fundamentals with a PE ratio of -61.29, profit margin of -23.66%, and ROE of -37.40%. The company generates $0.3B in annual revenue with strong year-over-year growth of 54.77%.

Key Strengths

PEG Ratio-52.96
Current Ratio3.97

Areas of Concern

ROE-37.40%
Operating Margin-16.18%
We analyze ADPT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -25.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-25.2/100

We analyze ADPT's fundamental strength across five key dimensions:

Efficiency Score

Weak

ADPT struggles to generate sufficient returns from assets.

ROA > 10%
-10.32%

Valuation Score

Excellent

ADPT trades at attractive valuation levels.

PE < 25
-61.29
PEG Ratio < 2
-52.96

Growth Score

Excellent

ADPT delivers strong and consistent growth momentum.

Revenue Growth > 5%
54.77%
EPS Growth > 10%
63.89%

Financial Health Score

Moderate

ADPT shows balanced financial health with some risks.

Debt/Equity < 1
2.32
Current Ratio > 1
3.97

Profitability Score

Weak

ADPT struggles to sustain strong margins.

ROE > 15%
-3740.04%
Net Margin ≥ 15%
-23.66%
Positive Free Cash Flow
No

Key Financial Metrics

Is ADPT Expensive or Cheap?

P/E Ratio

ADPT trades at -61.29 times earnings. This suggests potential undervaluation.

-61.29

PEG Ratio

When adjusting for growth, ADPT's PEG of -52.96 indicates potential undervaluation.

-52.96

Price to Book

The market values Adaptive Biotechnologies Corporation at 25.11 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

25.11

EV/EBITDA

Enterprise value stands at -156.66 times EBITDA. This is generally considered low.

-156.66

How Well Does ADPT Make Money?

Net Profit Margin

For every $100 in sales, Adaptive Biotechnologies Corporation keeps $-23.66 as profit after all expenses.

-23.66%

Operating Margin

Core operations generate -16.18 in profit for every $100 in revenue, before interest and taxes.

-16.18%

ROE

Management delivers $-37.40 in profit for every $100 of shareholder equity.

-37.40%

ROA

Adaptive Biotechnologies Corporation generates $-10.32 in profit for every $100 in assets, demonstrating efficient asset deployment.

-10.32%

Following the Money - Real Cash Generation

Operating Cash Flow

Adaptive Biotechnologies Corporation generates limited operating cash flow of $-4.26M, signaling weaker underlying cash strength.

$-4.26M

Free Cash Flow

Adaptive Biotechnologies Corporation generates weak or negative free cash flow of $-8.78M, restricting financial flexibility.

$-8.78M

FCF Per Share

Each share generates $-0.05 in free cash annually.

$-0.05

FCF Yield

ADPT converts -0.20% of its market value into free cash.

-0.20%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-61.29

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-52.96

vs 25 benchmark

P/B Ratio

Price to book value ratio

25.11

vs 25 benchmark

P/S Ratio

Price to sales ratio

14.77

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.32

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.97

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.37

vs 25 benchmark

ROA

Return on assets percentage

-0.10

vs 25 benchmark

ROCE

Return on capital employed

-0.08

vs 25 benchmark

How ADPT Stacks Against Its Sector Peers

MetricADPT ValueSector AveragePerformance
P/E Ratio-61.2930.84 Better (Cheaper)
ROE-37.40%573.00% Weak
Net Margin-23.66%5349.00% Weak
Debt/Equity2.32-0.03 (disorted) Distorted
Current Ratio3.975.76 Strong Liquidity
ROA-10.32%-254.00% (disorted) Weak

ADPT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Adaptive Biotechnologies Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

143.48%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

64.81%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

73.43%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ